• Publications
  • Influence
A phase 2 study of bortezomib in relapsed, refractory myeloma.
TLDR
Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Lenalidomide after stem-cell transplantation for multiple myeloma.
TLDR
Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma.
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
TLDR
It is demonstrated that the proteasome inhibitor PS-341 both acts directly on MM cells and alters cellular interactions and cytokine secretion in the BM millieu to inhibit tumor cell growth, induce apoptosis, and overcome drug resistance.
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
TLDR
The R-ISS is a simple and powerful prognostic staging system, and it is recommended for use in future clinical studies to stratify patients with NDMM effectively with respect to the relative risk to their survival.
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
TLDR
Bortezomib plus melphalan-prednisone alone in patients with newly diagnosed myeloma who were ineligible for high-dose therapy was superior to melphAlan-predisonsone alone.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
TLDR
Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death.
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
TLDR
The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma.
...
...